Brazil to secure good hep C prices, but what about other expensive drugs?
This article was originally published in Scrip
Executive Summary
The cost of hepatitis C drugs has prompted strong reactions across the world from India to Spain, but not so in Brazil where the government looks close to agreeing a favorable price with the manufacturers. Unfazed by its faltering economy and increasingly unsustainable healthcare system, Brazil's health ministry says it is set to offer free access to Bristol-Myers Squibb's Daklinza (daclatasvir), Gilead's Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir).